Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, ...

A custom NGS panel covering 27 IARC carcinogenic HPV genotypes enabled detection of ccfHPV DNA across treatment strata and ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

The results show that those with low vitamin D levels had a significantly higher risk of hospitalization related to respiratory tract infection compared with those whose 25 (OH)D levels were 75 nmol/L ...

Cost-effectiveness is highly price-sensitive; lower U.S. prices, particularly approaching European levels, shift semaglutide toward favorable value rather than a binary go/no-go determination. Patient ...

Risant’s CEO Jaewon Ryu discusses some of the early success of bringing a set of Kaiser Permanente’s value-based care ...

In the first segment of a video interview with MHE, the CEO of Risant Health discusses the role of scale in following ...

Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...

Becoming a qualified treatment center can take six to 18 months, according to Mahmoudjafari. Some institutions begin ...

The role of the pharmacist, managed care pharmacist job satisfaction and artificial intelligence were among the topics that Susan A. Cantrell, CEO of the Academy of Managed Care Pharmacy, discussed ...

In an hour and 48-minute speech that set the record for length for the State of the Union address, President Donald Trump spent less than five minutes on healthcare issues.

Hospitals and cancer centers that are launching cell and gene therapy programs need more than scientific breakthroughs to succeed. Delivering these therapies safely and efficientl ...